Yunnan Biovalley Pharmaceutical (BJ:833266) Zheng Quan Shi Bao Wang·2025-12-22 12:14Core Viewpoint - Yunnan Biological Valley Pharmaceutical Co., Ltd. has faced legal consequences for financial misconduct involving its former actual controller and financial director, highlighting the regulatory environment's strict stance against such violations [2][3]. Company Summary - Yunnan Biological Valley was established in 1999, focusing on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system drugs. The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [2]. - The former actual controller, Lin Yanhua, and the former financial director, He Yuan, were found guilty of misappropriating company funds for personal financial needs, leading to their convictions and sentences [2][3]. Regulatory Actions - In May 2022, the Yunnan Securities Regulatory Bureau initiated an investigation into the illegal activities, resulting in administrative penalties of 5 million yuan for Lin Yanhua and 2 million yuan for He Yuan, along with market entry bans [3]. - The case reflects the China Securities Regulatory Commission's commitment to combating financial misconduct and protecting the rights of small investors, emphasizing a zero-tolerance policy towards fund misappropriation [3].